Loading...
ALXBALEMS
Market cap3mUSD
Oct 21, Last price  
0.30EUR
Name

DMS Imaging SA

Chart & Performance

D1W1MN
ALXB:ALEMS chart
P/E
—
P/S
10.54
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
145.46%
Rev. gr., 5y
832.23%
Revenues
43m
+20.57%
754060401,064,841358,94436,270,00035,271,00042,525,000
Net income
-709k
L-87.29%
-2,319-4,429-7,715-12,339,000-11,986,000-14,321,000-15,656,000-1,362,000-241,000-5,578,000-709,000
CFO
-2m
L
-2,112-3,377-7,921-13,859,000-12,809,000-13,011,000-12,974,000-1,379,000348,0002,326,000-2,274,000
Earnings
Jan 16, 2025

Profile

DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
URL
https://www.asitbiotech.com/
IPO date
May 11, 2016
Employees
118
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
42,525
20.57%
35,271
-2.75%
36,270
10,004.64%
Cost of revenue
31,563
34,954
36,061
Unusual Expense (Income)
NOPBT
10,962
317
209
NOPBT Margin
25.78%
0.90%
0.58%
Operating Taxes
2
(161)
(377)
Tax Rate
0.02%
NOPAT
10,960
478
586
Net income
(709)
-87.29%
(5,578)
2,214.52%
(241)
-82.31%
Dividends
(521)
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
5,415
4,447
4,330
Long-term debt
17,329
10,340
9,171
Deferred revenue
1,592
531
531
Other long-term liabilities
227
198
347
Net debt
17,386
10,361
10,869
Cash flow
Cash from operating activities
(2,274)
2,326
348
CAPEX
(2,569)
(2,210)
(1,921)
Cash from investing activities
(1,507)
(992)
(1,343)
Cash from financing activities
3,743
471
2,003
FCF
9,109
1,839
(17,636)
Balance
Cash
5,159
4,232
2,427
Long term investments
199
194
205
Excess cash
3,232
2,662
818
Stockholders' equity
66,148
(27,990)
10,551
Invested Capital
28,202
49,863
19,780
ROIC
28.08%
1.37%
1.83%
ROCE
36.73%
1.21%
0.83%
EV
Common stock shares outstanding
148,961
1,489,607
21,893
Price
Market cap
EV
EBITDA
11,675
2,454
2,142
EV/EBITDA
Interest
717
Interest/NOPBT
6.54%